Rituximab and Trastuzumab Biosimilars Shown to Have Economic Advantage Over Originators
Jacopo Giuliani, MD, discusses the analysis of the economic impact of biosimilars in breast cancer and follicular lymphoma.
Related Articles
Dr Powles on Implications of the CREST Study of Sasanlimab Plus BCG in BCG-Naive NMIBC
Thomas Powles, MD, MBBS, MRCP, discusses the implications of data from sasanlimab plus BCG in patients with BCG-naive, high-risk NMIBC.
FDA Grants Orphan Drug Designation to SENTI-202 for R/R AML and Hematologic Malignancies
SENTI-202 receives FDA orphan drug designation for treating relapsed/refractory hematologic malignancies, including AML.
Zanubrutinib/Venetoclax Yields Deep Responses in Treatment-Naive CLL Regardless of Del17p/TP53 Mutational Status
Mazyar Shadman, MD, MPH, discusses key efficacy and safety findings from arm D of the SEQUOIA trial of first-line zanubrutinib plus venetoclax in CLL/SLL.
Dr McArthur on the Efficacy of Pembrolizumab Plus Neoadjuvant Chemo in TNBC
Heather McArthur, MD, MPH, FASCO, discusses the efficacy of pembrolizumab/chemo and sequencing the regimen in early triple-negative breast cancer.
Ibrutinib Plus Venetoclax and A CD20 Monoclonal Antibody Increases MRD Negativity in Untreated MCL
Treatment with ibrutinib plus venetoclax and a CD20 monoclonal antibody induced high MRD negativity rates vs ibrutinib/anti-CD20 in untreated MCL.
MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL
A matching-adjusted indirect comparison of zanubrutinib and acalabrutinib/venetoclax showed favorability towards zanubrutinib in patients with CLL.
Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma
Results from dose level G of MagnetisMM-6 found high response rates with an elranatamab triplet in patients with newly diagnosed multiple myeloma.
FDA Grants Orphan Drug Designation to CID-078 for SCLC
The FDA has granted orphan drug designation to CID-078 for the treatment of patients with small cell lung cancer.
QOL Data Could Help Support Switch to Camizestrant in HR+ Breast Cancer After Emergence of ESR1 Mutation
Hope S. Rugo, MD, breaks down the implications of data from SERENA-6 for the management of emergent ESR1-mutant, HR–positive breast cancer.
ASCO 2025 Showcases Emerging Data on MRD-Guided Therapy, Trispecific Antibodies, and Frontline Bispecifics in Myeloma
Amrita Krishnan, MD, discusses key data may shape the evolving treatment landscape of multiple myeloma from ASCO 2025.